NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

10815	Companies
234295	Keywords
163067	Articles
125276	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 10/20/2025 at 14:45, 9 months 20 days ago

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus
NanoViricides, Inc. announces NV-387, a drug showing strong activity against Measles virus in an animal model, available for emergency use. Drug has completed Phase I clinical trial

NanoViricides NV-387 Emergency Use Measles Virus Phase I
BRIEF

published on 10/15/2025 at 14:50, 9 months 25 days ago

NanoViricides poursuit une stratégie clinique à double voie pour le NV-387

Antiviral À Large Spectre Essais De Phase II Développement NV-387 Essai MPox Virus Respiratoires
BRIEF

published on 10/15/2025 at 14:50, 9 months 25 days ago

NanoViricides Pursues Dual-Track Clinical Strategy for NV-387

Respiratory Viruses Broad-spectrum Antiviral Phase II Trials NV-387 Development MPox Trial
PRESS RELEASE

published on 10/15/2025 at 14:45, 9 months 25 days ago

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses
NanoViricides, Inc. reveals dual-track clinical development strategy for NV-387 targeting respiratory viral infections including Influenzas, Coronaviruses, RSV. Analyst report details trials and future prospects

Respiratory Viral Infections NV-387 NanoViricides Inc. Analyst Report Clinical Development Strategy
BRIEF

published on 09/30/2025 at 14:50, 10 months 9 days ago

Progrès du NV-387 de NanoViricides dans les essais cliniques

NanoViricides NV-387 Essais Cliniques Thérapie Antivirale Défis De Financement
BRIEF

published on 09/30/2025 at 14:50, 10 months 9 days ago

NanoViricides' NV-387 Advances in Clinical Trials

NanoViricides NV-387 Clinical Trials Antiviral Therapy Funding Challenges
PRESS RELEASE

published on 09/30/2025 at 14:45, 10 months 9 days ago

NanoViricides, Inc. Has Filed its Annual Report
NanoViricides reports progress on antiviral NV-387 in Phase II clinical trials with potential to revolutionize treatment for respiratory viral infections. Annual report highlights achievements and funding status

NanoViricides NV-387 Clinical Trials Respiratory Infections Antiviral
BRIEF

published on 09/11/2025 at 14:35, 10 months 28 days ago

NanoViricides sera présenté au congrès mondial LSX à Boston

NanoViricides NV-387 Essais Cliniques Médicament Antiviral Congrès LSX
BRIEF

published on 09/11/2025 at 14:35, 10 months 28 days ago

NanoViricides to Present at LSX World Congress in Boston

NanoViricides NV-387 Clinical Trials Antiviral Drug LSX Congress
PRESS RELEASE

published on 09/11/2025 at 14:30, 10 months 28 days ago

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
NanoViricides, Inc. announces participation in LSX World Congress 2025 to present revolutionary broad-spectrum antiviral drug NV-387 and potential impact on viral infections

NanoViricides NV-387 Antiviral Drug Viral Infections LSX World Congress

Accesswire

Published on 08/08/2026 at 00:00, 2 days 7 hours ago

Boron One Announces Change of Auditor
Published on 08/07/2026 at 23:15, 2 days 8 hours ago

Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 2 days 8 hours ago

Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/07/2026 at 22:30, 2 days 9 hours ago

UraniumX Deploys $3.8 Million to Athabasca Basin Exploration
Published on 08/07/2026 at 22:15, 2 days 9 hours ago

Noram Lithium Engages 1353656 BC Ltd. for Marketing and Management Consulting Services

View all ACCESSWIRE

EQS Group

Published on 08/10/2026 at 07:10, 24 minutes ago

Hypoport delivers solid gross profit growth and marked EBIT increase in first half of 2026
Published on 08/10/2026 at 07:00, 34 minutes ago

Infracore SA announces partial exercise of the over-allotment option
Published on 08/10/2026 at 07:00, 34 minutes ago

Infracore SA annonce l’exercice partiel de l’option de surallocation
Published on 08/10/2026 at 07:00, 34 minutes ago

MindMaze Therapeutics Completes Organizational Simplification and Provides Update on Neuro.io Equity Financing
Published on 08/10/2026 at 07:00, 34 minutes ago

ARYZTA protects profitability in a demanding environment; Capital returns to resume in 2027; Reviewing all options for Germany

Les Echos

Published on 08/10/2026 at 07:00, 34 minutes ago

BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY
Published on 08/10/2026 at 07:00, 34 minutes ago

Biophytis annonce l’autorisation de l’étude clinique OBA au Brésil et partage les perspectives de BIO101 dans l’obésité
Published on 08/07/2026 at 18:54, 2 days 12 hours ago

Covivio - Déclaration des transactions sur actions propres réalisées du 03 août 2026 au 07 août 2026
Published on 08/07/2026 at 18:54, 2 days 12 hours ago

Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 2 days 12 hours ago

Disclosure of transactions in own shares from August 3 to August 7, 2026

View all LES ECHOS COMFI WIRE